Silence Therapeutics (SLN) Competitors $5.54 -0.15 (-2.55%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLN vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Silence Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech ARAVIVE Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Silence Therapeutics (NASDAQ:SLN) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment. Do analysts rate SLN or ATNFW? Silence Therapeutics currently has a consensus price target of $33.83, indicating a potential upside of 510.16%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in SLN or ATNFW? 98.7% of Silence Therapeutics shares are owned by institutional investors. 4.1% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to SLN or ATNFW? In the previous week, Silence Therapeutics' average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment Silence Therapeutics Neutral 180 Life Sciences Neutral Is SLN or ATNFW more profitable? 180 Life Sciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -260.55%. 180 Life Sciences' return on equity of 0.00% beat Silence Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silence Therapeutics-260.55% -56.17% -33.96% 180 Life Sciences N/A N/A N/A Which has preferable earnings and valuation, SLN or ATNFW? 180 Life Sciences has lower revenue, but higher earnings than Silence Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilence Therapeutics$43.26MN/A-$45.31M-$1.50-3.70180 Life SciencesN/AN/AN/AN/AN/A SummarySilence Therapeutics beats 180 Life Sciences on 6 of the 9 factors compared between the two stocks. Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLN vs. The Competition Export to ExcelMetricSilence TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$2.41B$5.50B$9.01BDividend YieldN/A1.77%5.39%4.11%P/E Ratio-3.708.9727.4220.07Price / SalesN/A467.40398.50109.13Price / CashN/A151.5836.1356.90Price / Book1.244.618.015.70Net Income-$45.31M$31.34M$3.16B$248.47M7 Day Performance0.09%0.86%2.08%2.92%1 Month Performance2.50%7.90%4.38%5.77%1 Year Performance-69.14%1.89%35.81%21.39% Silence Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNSilence Therapeutics2.9143 of 5 stars$5.55-2.5%$33.83+510.2%-68.5%$0.00$43.26M-3.70100ATNFW180 Life SciencesN/A$0.01-3.4%N/A-14.6%$0.00N/A0.007Gap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/A-77.2%$0.00N/A0.002AIMDWAinosN/A$0.18+6.1%N/AN/A$0.00$106.21K0.0040Gap UpALVOWAlvotechN/A$1.73+1.8%N/A-42.3%$0.00$585.60M0.004Positive NewsARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03+6.5%N/A-74.1%$0.00N/A0.0015BFRIWBiofronteraN/A$0.09-14.6%N/AN/A$0.00$38.00M0.0070Positive NewsBTMDWbioteN/A$0.02-41.2%N/A-97.9%$0.00$199.38M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.06-11.2%N/A-68.7%$0.00N/A0.008Gap Down Related Companies and Tools Related Companies ATNFW Alternatives LBPSW Alternatives AEHAW Alternatives AIMDW Alternatives ALVOW Alternatives ARAV Alternatives ACABW Alternatives BFRIW Alternatives BTMDW Alternatives BCTXW Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLN) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
